📄 NUVOX THERAPEUTICS, INC.

NuvOx Therapeutics is a clinical-stage biopharmaceutical company developing NanO2, an oxygen therapeutic designed to treat diseases where hypoxia plays a critical role, such as acute ischemic stroke, glioblastoma (GBM), acute respiratory distress syndrome (ARDS), and sickle cell anemia. NanO2 is an intravenously administered emulsified liquid with nano-sized droplets that convert to gas in the body to deliver oxygen to tissues. The company has completed Phase Ib/IIa trials in stroke and GBM and is currently conducting Phase IIb trials in GBM and stroke, as well as a Phase Ib trial in respiratory distress. Offering: $17.4M at $91.7M valuation Key risk: We are a development-stage company with a limited operating history and have not yet obtained approval for any product candidate, making our future prospects highly uncertain. Proceeds: Approximately $5.0 million to fund through clinical trial completion the current Phase IIb clinical trial in GBM, Approximately $0.5 million to fund pr

NuvOx Therapeutics is a clinical-stage biopharmaceutical company developing NanO2, an oxygen therapeutic designed to treat diseases where hypoxia plays a critical role, such as acute ischemic stroke, glioblastoma (GBM), acute respiratory distress syndrome (ARDS), and sickle cell anemia. NanO2 is an intravenously administered emulsified liquid with nano-sized droplets that convert to gas in the body to deliver oxygen to tissues. The company has completed Phase Ib/IIa trials in stroke and GBM and is currently conducting Phase IIb trials in GBM and stroke, as well as a Phase Ib trial in respiratory distress.